The Biochemical and Molecular Analysis of Changes in Melanogenesis Induced by UVA-Activated Fluoroquinolones-In Vitro Study on Human Normal Melanocytes.
Cell Death
/ drug effects
Cell Survival
/ drug effects
Fluoroquinolones
/ chemistry
Gene Expression Regulation
/ drug effects
Humans
Melanins
/ biosynthesis
Melanocytes
/ drug effects
Microphthalmia-Associated Transcription Factor
/ genetics
Monophenol Monooxygenase
/ genetics
Moxifloxacin
/ chemistry
RNA, Messenger
/ genetics
Ultraviolet Rays
lomefloxacin
melanin
melanogenesis
microphthalmia-associated transcription factor
moxifloxacin
tyrosinase
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
27 10 2021
27 10 2021
Historique:
received:
25
07
2021
revised:
15
10
2021
accepted:
25
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
14
1
2022
Statut:
epublish
Résumé
Fluoroquinolones cause phototoxic reactions, manifested as different types of skin lesions, including hyperpigmentation. The disturbances of melanogenesis indicate that fluoroquinolones may affect cellular processes in melanocytes. It has been reported that these antibiotics may bind with melanin and accumulate in pigmented cells. The study aimed to examine the changes in melanogenesis in human normal melanocytes exposed to UVA radiation and treated with lomefloxacin and moxifloxacin, the most and the least fluoroquinolone, respectively. The obtained results demonstrated that both tested fluoroquinolones inhibited melanogenesis through a decrease in tyrosinase activity and down-regulation of tyrosinase and microphthalmia-associated transcription factor production. Only lomefloxacin potentiated UVA-induced melanogenesis. Under UVA irradiation lomefloxacin significantly enhanced melanin content and tyrosinase activity in melanocytes, although the drug did not cause an increased expression of tyrosinase or microphthalmia-associated transcription factor. The current studies revealed that phototoxic activity of fluoroquinolones is associated with alterations in the melanogenesis process. The difference in phototoxic potential of fluoroquinolones derivatives may be connected with various effects on UVA-induced events at a cellular level.
Identifiants
pubmed: 34831123
pii: cells10112900
doi: 10.3390/cells10112900
pmc: PMC8616096
pii:
doi:
Substances chimiques
Fluoroquinolones
0
MITF protein, human
0
Melanins
0
Microphthalmia-Associated Transcription Factor
0
RNA, Messenger
0
Monophenol Monooxygenase
EC 1.14.18.1
lomefloxacin
L6BR2WJD8V
Moxifloxacin
U188XYD42P
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Śląski Uniwersytet Medyczny
ID : PCN-1-097/K/0/F, PCN-2-042/N/0/F
Références
Pigment Cell Res. 1997 Jun;10(3):127-38
pubmed: 9266599
Int J Mol Sci. 2013 Jun 07;14(6):12222-48
pubmed: 23749111
Protein Sci. 2015 Sep;24(9):1360-9
pubmed: 26104241
Chem Biol Interact. 2018 Jun 25;290:57-63
pubmed: 29800573
Pharmacol Rep. 2018 Feb;70(1):6-13
pubmed: 29306115
Dermatol Online J. 2018 Jul 15;24(7):
pubmed: 30261569
Toxicol In Vitro. 2019 Mar;55:75-92
pubmed: 30528372
Int J Biochem Cell Biol. 2013 Jul;45(7):1217-22
pubmed: 23523934
Skin Pharmacol Physiol. 2009;22(2):114-21
pubmed: 19188759
Arch Pharm (Weinheim). 2018 Sep;351(9):e1800141
pubmed: 30048015
Pharmacol Rep. 2013;65(3):689-99
pubmed: 23950592
Antimicrob Agents Chemother. 1992 Aug;36(8):1715-9
pubmed: 1329627
Mol Cell Biochem. 2015 Mar;401(1-2):107-14
pubmed: 25433710
J Antimicrob Chemother. 2009 Feb;63(2):343-8
pubmed: 19109335
Biochem Biophys Res Commun. 2004 Dec 24;325(4):1412-7
pubmed: 15555584
Physiol Rev. 2004 Oct;84(4):1155-228
pubmed: 15383650
J Invest Dermatol. 2003 Sep;121(3):596-606
pubmed: 12925221
Acta Pol Pharm. 2009 Nov-Dec;66(6):587-604
pubmed: 20050522
Pigment Cell Melanoma Res. 2012 Jan;25(1):14-27
pubmed: 21834848
Am Fam Physician. 2002 Feb 1;65(3):455-64
pubmed: 11858629
Pigment Cell Melanoma Res. 2019 Mar;32(2):224-236
pubmed: 30019545
Chem Biol Interact. 2019 Apr 25;303:27-34
pubmed: 30768968
Lab Invest. 2017 Jun;97(6):649-656
pubmed: 28263292
Postepy Hig Med Dosw (Online). 2016 Jun 30;70(0):695-708
pubmed: 27356601
Cutan Ocul Toxicol. 2017 Jun;36(2):169-175
pubmed: 27572617
Clin Cornerstone. 2003;Suppl 3:S29-36
pubmed: 14992418
Pigment Cell Melanoma Res. 2015 Sep;28(5):520-44
pubmed: 26176788
J Am Board Fam Med. 2019 Jul-Aug;32(4):628-638
pubmed: 31300585
Antimicrob Agents Chemother. 1993 Oct;37(10):2217-23
pubmed: 8257147
Pigment Cell Res. 2002 Jun;15(3):162-73
pubmed: 12028580
Pharmaceuticals (Basel). 2021 Jul 26;14(8):
pubmed: 34451820
J Invest Dermatol. 1993 Jun;100(6):806-11
pubmed: 8496620
Clin Dermatol. 2016 Sep-Oct;34(5):571-81
pubmed: 27638435
Arch Pharm (Weinheim). 2019 Jul;352(7):e1800376
pubmed: 31215674
Ann Afr Med. 2018 Jan-Mar;17(1):40-42
pubmed: 29363635
Pharmacol Rep. 2015 Feb;67(1):38-43
pubmed: 25560573
Surv Ophthalmol. 2004 Mar;49 Suppl 2:S73-8
pubmed: 15028482
J Am Acad Dermatol. 2014 Sep;71(3):e82-3
pubmed: 25128136
J Am Acad Dermatol. 1995 Oct;33(4):551-73; quiz 574-6
pubmed: 7673488
Int J Mol Sci. 2020 Dec 19;21(24):
pubmed: 33352719
Antimicrob Agents Chemother. 2009 Jan;53(1):312-5
pubmed: 19015358
Int J Mol Sci. 2017 Oct 20;18(10):
pubmed: 29053584
Pigment Cell Res. 1993 Jun;6(3):127-33
pubmed: 8234197
Exp Dermatol. 2010 Jul 1;19(7):617-27
pubmed: 20201954
Ocul Immunol Inflamm. 2006 Dec;14(6):347-51
pubmed: 17162605
Postepy Dermatol Alergol. 2013 Feb;30(1):30-41
pubmed: 24278043
Endocrinology. 2018 May 1;159(5):1992-2007
pubmed: 29546369
J Phys Chem B. 2006 Apr 6;110(13):6441-3
pubmed: 16570937